Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.
Also called NCT07719894
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,200 participants
- Registry
-
NCT07719894
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07719894. Randomized; no masking; primary purpose treatment. Start 2026-05-06 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
- Acronym
- Cilo-Asa
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Condition
- Atherosclerosis
- Intervention (Drug)
- Cilostazol
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Seoul National University Bundang Hospital
Record details
- Record id
cardio:ct-nct07719894- Content hash
b17ef3cf2c15f67ac43e7499b3528957d076347d7d501921ca0573c700391d16